Skip to main content
Eligibility
for people ages 12 months to 21 years
Location
at San Francisco, California and other locations
Dates
study started
estimated completion:
Principal Investigator

Description

Summary

The main purpose of this study is to evaluate the safety of the study drug known as ramucirumab in children with recurrent or refractory solid tumors including central nervous system (CNS) tumors.

Official Title

A Phase 1 Study Of Ramucirumab, a Human Monoclonal Antibody Against the Vascular Endothelial Growth Factor-2 (VEGFR-2) Receptor in Children With Refractory Solid Tumors, Including CNS Tumors

Keywords

Pediatric Solid Tumor Refractory Tumor Recurrent Tumor CNS Malignancies relapsed pediatric solid tumors unspecified childhood solid tumor brain and central nervous system tumors Endothelial Growth Factors Ramucirumab

Eligibility

You can join if…

Open to people ages 12 months to 21 years

  • Part A: participants with recurrent or refractory non-CNS solid tumors
  • Part B: participants with recurrent or refractory CNS tumors
  • Measurable or evaluable disease
  • No other therapeutic options
  • Performance Status: Karnofsky ≥50% for participants>16 years and Lansky ≥50 for participants ≤16 years

You CAN'T join if...

  • Active or recent history of serious bleeding events
  • Active or recent history of gastrointestinal perforations, ulcers, fistulas or abscesses
  • Active or recent history of hypertensive crisis or hypertensive encephalopathy
  • Active non-healing wound or bone fracture
  • History of solid organ transplant

Locations

  • SMO Children's Oncology Group accepting new patients
    Monrovia, California, 91016, United States
  • Childrens Hospital of Orange County accepting new patients
    Orange, California, 92868, United States

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Eli Lilly and Company
Links
Click here for more information about this study: A Study of Ramucirumab (LY3009806) in Children With Refractory Solid Tumors
ID
NCT02564198
Phase
Phase 1
Lead Scientist
Katherine Matthay
Study Type
Interventional
Last Updated
March 1, 2017
I'm interested in this study!